Institution
Barzilai Medical Center
Healthcare•Ashqelon, Israel•
About: Barzilai Medical Center is a healthcare organization based out in Ashqelon, Israel. It is known for research contribution in the topics: Population & Diabetes mellitus. The organization has 673 authors who have published 878 publications receiving 21911 citations. The organization is also known as: Ashkelon Hospital & Merkaz ha-refuʼi Barzilai Ashḳelon.
Topics: Population, Diabetes mellitus, Blood pressure, In vitro fertilisation, Retrospective cohort study
Papers published on a yearly basis
Papers
More filters
••
TL;DR: These genetic data for ACE2 show that it is an essential regulator of heart function in vivo and targeted disruption of ACE2 in mice results in a severe cardiac contractility defect, increased angiotensin II levels, and upregulation of hypoxia-induced genes in the heart.
Abstract: Cardiovascular diseases are predicted to be the most common cause of death worldwide by 2020. Here we show that angiotensin-converting enzyme 2 (ace2) maps to a defined quantitative trait locus (QTL) on the X chromosome in three different rat models of hypertension. In all hypertensive rat strains, ACE2 messenger RNA and protein expression were markedly reduced, suggesting that ace2 is a candidate gene for this QTL. Targeted disruption of ACE2 in mice results in a severe cardiac contractility defect, increased angiotensin II levels, and upregulation of hypoxia-induced genes in the heart. Genetic ablation of ACE on an ACE2 mutant background completely rescues the cardiac phenotype. But disruption of ACER, a Drosophila ACE2 homologue, results in a severe defect of heart morphogenesis. These genetic data for ACE2 show that it is an essential regulator of heart function in vivo.
1,630 citations
••
TL;DR: Cadesartan 16 mg once daily is as effective as lisinopril 20 mgonce daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes and combination treatment is well tolerated and more effective in reducingBlood pressure.
Abstract: Objectives: To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes. Design: Prospective, randomised, parallel group, double blind study with four week placebo run in period and 12 weeks9 monotherapy with candesartan or lisinopril followed by 12 weeks9 monotherapy or combination treatment. Setting: Tertiary hospitals and primary care centres in four countries (37 centres). Participants: 199 patients aged 30-75 years. Interventions: Candesartan 16 mg once daily, lisinopril 20 mg once daily. Main outcome measures: Blood pressure and urinary albumin:creatinine ratio. Results: At 12 weeks mean (95% confidence interval) reductions in diastolic blood pressure were 9.5 mm Hg (7.7 mm Hg to 11.2 mm Hg, P Conclusion: Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes. Combination treatment is well tolerated and more effective in reducing blood pressure.
1,027 citations
••
TL;DR: Automatic, daily, implant-based, multiparameter telemonitoring can significantly improve clinical outcomes for patients with heart failure and should be used in clinical practice.
587 citations
••
Shaare Zedek Medical Center1, Hebrew University of Jerusalem2, Kaplan Medical Center3, Tel Aviv University4, Ben-Gurion University of the Negev5, Ankara University6, Istanbul University7, University of Washington8, University of Miami9, Erciyes University10, Rabin Medical Center11, Barzilai Medical Center12, Stanford University13, Technische Universität München14
TL;DR: Recessive loss-of-function mutations of ADA2, a growth factor that is the major extracellular adenosine deaminase, can cause polyarteritis nodosa vasculopathy with highly varied clinical expression.
Abstract: BACKGROUND Polyarteritis nodosa is a systemic necrotizing vasculitis with a pathogenesis that is poorly understood. We identified six families with multiple cases of systemic and cutaneous polyarteritis nodosa, consistent with autosomal recessive inheritance. In most cases, onset of the disease occurred during childhood. METHODS We carried out exome sequencing in persons from multiply affected families of Georgian Jewish or German ancestry. We performed targeted sequencing in additional family members and in unrelated affected persons, 3 of Georgian Jewish ancestry and 14 of Turkish ancestry. Mutations were assessed by testing their effect on enzymatic activity in serum specimens from patients, analysis of protein structure, expression in mammalian cells, and bio physical analysis of purified protein. RESULTS In all the families, vasculitis was caused by recessive mutations in CECR1, the gene encoding adenosine deaminase 2 (ADA2). All the Georgian Jewish patients were homozygous for a mutation encoding a Gly47Arg substitution, the German patients were compound heterozygous for Arg169Gln and Pro251Leu mutations, and one Turkish patient was compound heterozygous for Gly47Val and Trp264Ser mutations. In the endogamous Georgian Jewish population, the Gly47Arg carrier frequency was 0.102, which is consistent with the high prevalence of disease. The other mutations either were found in only one family member or patient or were extremely rare. ADA2 activity was significantly reduced in serum specimens from patients. Expression in human embryonic kidney 293T cells revealed low amounts of mutant secreted protein. CONCLUSIONS Recessive loss-of-function mutations of ADA2, a growth factor that is the major extracellular adenosine deaminase, can cause polyarteritis nodosa vasculopathy with highly varied clinical expression. (Funded by the Shaare Zedek Medical Center and others.)
531 citations
••
TL;DR: When given to patients with acute heart failure and normal-to-increased blood pressure, relaxin was associated with favourable relief of dyspnoea and other clinical outcomes, with acceptable safety.
417 citations
Authors
Showing all 676 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ron Milo | 69 | 215 | 32189 |
Yehuda Chowers | 60 | 211 | 14526 |
Yaniv Sherer | 48 | 151 | 7831 |
Chaim Brautbar | 42 | 195 | 8831 |
Rachel Levy | 41 | 181 | 6834 |
Roy Homburg | 39 | 149 | 4771 |
Eli Eliav | 39 | 131 | 4571 |
Shraga Segal | 38 | 184 | 5876 |
Raoul Orvieto | 37 | 241 | 4495 |
Ruth Defrin | 34 | 105 | 3506 |
Igor Kaiserman | 33 | 167 | 3924 |
Jonathan Benjamin | 32 | 65 | 9812 |
Esther Kahana | 31 | 74 | 3677 |
Amos Katz | 31 | 147 | 5598 |
Boris Yoffe | 30 | 103 | 3369 |